Thyroid dysfunction and tyrosine kinase inhibitors in renal cell carcinoma

Endocrine-Related Cancer

Volumn 20, Issue 5, 2013, Pages

  Bianchi, Loredana ^a   Rossi, Luigi ^a   Tomao, Federica ^a   Papa, Anselmo ^a   Zoratto, Federica ^a   Tomao, Silverio ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Carcinoma; Hypothyroidism; Metastatic renal cell; Tyrosine kinase inhibitors; VEGF

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; AXITINIB; BEVACIZUMAB; EVEROLIMUS; LIOTHYRONINE; PAZOPANIB; PROTEIN TYROSINE KINASE; RADIOACTIVE IODINE; SORAFENIB; SUNITINIB; TEMSIROLIMUS; THYROID HORMONE; THYROTROPIN; THYROXINE;

ANEMIA; ANOREXIA; BLEEDING; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; DIARRHEA; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED DISEASE; DRUG SAFETY; DYSPNEA; EMBOLISM; FATIGUE; HAND FOOT SYNDROME; HEART LEFT VENTRICLE FAILURE; HORMONE SUBSTITUTION; HUMAN; HYPERAMYLASEMIA; HYPERBILIRUBINEMIA; HYPERCREATININEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPOPHOSPHATEMIA; HYPOTHYROIDISM; KIDNEY CARCINOMA; LIOTHYRONINE BLOOD LEVEL; LYMPHOCYTIC THYROIDITIS; LYMPHOCYTOPENIA; MUCOSA INFLAMMATION; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROTEINURIA; RASH; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; STOMATITIS; SUBCLINICAL HYPOTHYROIDISM; SURVIVAL RATE; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; THROMBOSIS; THYROID FUNCTION; THYROID GLAND; THYROID HORMONE METABOLISM; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

EID: 84886424099     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-13-0201     Document Type: Review

References (115)

1. Abdulrahman RM, Verloop H, Hoftijzer H, Verburg E, Hovens GC, Corssmit EP, Reiners C, Gelderblom H, Pereira AM, Kapiteijn E et al. 2010 Sorafenib-induced hypothyroidism is associated with increased type 3 deiodination. Journal of Clinical Endocrinology and Metabolism 95 3758-3762. (doi:10.1210/jc.2009-2507)
2. Abrams TJ, Lee LB, Murray LJ, Prjer NK & Cherrington JM 2003 SU11248 inhibit KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Molecular Cancer Therapeutics 2 471-478.
3. Alexandrescu DT, Popoveniuc G, Farzanmehr H, Dasanu CA, Dawson N & Wartofsky L 2008 Sunitinib associated lymphocytic thyroiditis without circulating antithyroid antibodies. Thyroid 18 809-812. (doi:10.1089/ thy.2007.0349)
4. American Cancer Society: Cancer Facts and Figures 2012. Atlanta GACS, 2012. Atlanta, GA, USA: American Cancer Society.
5. Andersson M, de Benoist B, Delange F & Zupan J 2007 Prevention and control of iodine deficiency in pregnant and lactating women and in children less than 2-years-old: conclusions and recommendations of the Technical Consultation. Public Health Nutrition 10 1606-1611. (doi:10.1017/ S1368980007000092)
6. Aparicio-Gallego G, Blanco M, Figueroa A, García-Campelo R, Valladares-Ayerbes M, Grande-Pulido E & Antón-Aparicio L 2011 New insight into molecular mechanism of sunitinib-associated side effect. Molecular Cancer Therapeutics 10 2215-2223. (doi:10.1158/ 1535-7163.MCT-10-1124)
7. Baffert F, Le T, Sennino B, Thurston G, Kuo CJ, Hu-Lowe D& McDonaldDM 2006 Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling. American Journal of Physiology. Heart and Circulatory Physiology 290 H547-H559. (doi:10.1152/ajpheart.00616.2005)
8. Baldazzi V, Tassi R, Lapini A, Santomaggio C, Carini M & Mazzanti R 2012 The impact of sunitinib-induced hypothyroidism on progression-free survival of metastatic renal cancer patients: a prospective singlecenter study. Urologic Oncology 30 704-710. (doi:10.1016/j.urolonc. 2010.07.015)
9. Beck-Peccoz P, Amr S, Menezes-Ferreira MM, Faglia G& Weintraub BD 1985 Decreased receptor binding of bio-logically inactive thyrotropin in central hypothyroidism. Effect of treatment with thyrotropin-releasing hormone. New England Journal of Medicine 312 1085-1090. (doi:10.1056/NEJM198504253121703)
10. Braun D, Kim TD, le Coutre P, Kohrle J, Hershman JM & Schweizer U 2012 Tyrosine kinase inhibitors noncompetitively inhibit MCT8-mediated iodothyronine transport. Journal of Clinical Endocrinology and Metabolism 97 E100-E105. (doi:10.1210/jc.2011-1837)
11. Calebiro D, de Filippis T, Lucchi S, Martinez F, Porazzi P, Trivellato R, Locati M, Beck-Peccoz P & Persani L 2006 Selective modulation of protein kinase A I and II reveals distinct roles in thyroid cell gene expression and growth. Molecular Endocrinology 20 3196-3211. (doi:10.1210/me.2005-0493)
12. Castellano D, Ravaud A, Schmidinger M, De Velasco G & Vazquez F 2013 Therapy management with sunitinib in patients with metastatic renal cell carcinoma: key concepts and the impact of clinical biomarkers. Cancer Treatment Reviews 39 230-240. (doi:10.1016/j.ctrv.2012.04.009)
13. Chakera AJ, Pearce SHS & Vaidya B 2012 Treatment for primary hypothyroidism: current approaches and future possibilities. Drug Design, Development and Therapy 6 1-11.
14. Clemons J, Gao D, NaamM, Breaker K, Garfield D & Flaig TW2012 Thyroid dysfunction in patients treated with sunitinib or sorafenib. Clinical Genitourinary Cancer 10 225-231. (doi:10.1016/j.clgc.2012.08.002)
15. Cohen EE, Rosen LS, Vokes EE, Kies MS, Forastiere AA, Worden FP, Kane MA, Sherman E, Kim S, Bycott P et al. 2008 Axitinib is an active treatment for allhistologic subtypes of advanced thyroid cancer: results from a phase II study. Journal of Clinical Oncology 26 4708-4713. (doi:10.1200/JCO. 2007.15.9566)
16. Cristofanilli M, Yamamura Y, Kau SW, Bevers T, Strom S, Patangan M, Hsu L, Krishnamurthy S, Theriault RL&HortobagyiGN2005 Thyroid hormone and breast carcinoma. Primary hypothyroidism is associated with a reduced incidence of primary breast carcinoma. Cancer 103 1122-1128. (doi:10.1002/cncr.20881)
17. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA et al. 2006 Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368 1329-1338. (doi:10.1016/S0140-6736(06) 69446-4)
18. Dentice M, Ambrosio R & Salvatore D 2009 Role of type 3 deiodinase in cancer. Expert Opinion on Therapeutic Targets 13 1363-1373. (doi:10.1517/14728220903339122)
19. Desai J, Yassa L, Marqusee E, George S, Frates MC, Chen MH, Morgan JA, Dychter SS, Larsen PR, Demetri GD et al. 2006 Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Annals of Internal Medicine 145 660-664. (doi:10.7326/0003-4819-145- 9-200611070-00008)
20. Di Lorenzo G, Porta C, Bellmunt J, Sternberg C, Kirkali Z, Staehler M, Joniau S, Montorsi F & Buonerba C 2011 Toxicities of targeted therapy and their management in kidney cancer. European Urology 59 526-540. (doi:10.1016/j.eururo.2011.01.002)
21. Eisen T, Sternberg CN, Robert C, Mulders P, Pyle L, Zbinden S, Izzedine H & Escudier B 2012 Targeted therapies for renal cell carcinoma: review of adverse event management strategies. Journal of the National Cancer Institute 104 93-113. (doi:10.1093/jnci/djr511)
22. Ellis LM & Hicklin DJ 2008 VEGF-targeted therapy: mechanisms of antitumour activity. Nature Reviews. Cancer 8 579-591. (doi:10.1038/ nrc2403)
23. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA et al. 2007a Sorafenib in advanced clearcell renal carcinoma. New England Journal of Medicine 356 125-134. (doi:10.1056/NEJMoa060655)
24. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B & Bajetta E 2007b Bevacizumab plus interferon a-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370 2103-2111. (doi:10.1016/S0140-6736(07) 61904-7)
25. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Staehler M, Negrier S, Chevreau C, Desai AA, Rolland F et al. 2009 Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. Journal of Clinical Oncology 27 3312-3318. (doi:10.1200/JCO.2008.19.5511)
26. Faivre S, Demetri G, Sargent W & Raymond E 2007 Molecular basis for sunitinib efficacy and future clinical development. Nature Reviews. Drug Discovery 6 734-745. (doi:10.1038/nrd2380)
27. Ferlay J, Parkin DM & Steliarova-Foucher E 2010 Estimates of cancer incidence and mortality in Europe in 2008. European Journal of Cancer 46 765-781. (doi:10.1016/j.ejca.2009.12.014)
28. Fratto ME, Imperatori M, Vincenzi B, Tomao F, Santini D & Tonini G 2011 New perspectives: role of sunitinib in breast cancer. La Clinica Terapeutica 162 251-257.
29. Fujiwara Y, Kiyota N, Chayahara N, Suzuki A, Umeyama Y, Mukohara T & Minami H 2012 Management of axitinib (AG-013736) -induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients. Investigational New Drugs 30 1055-1064. (doi:10.1007/s10637-011-9637-1)
30. Garber JR, Cobin RH, Gharib H, Hennessey JV, Klein I, Mechanick JI, Pessah-Pollack R, Singer PA & Woeber KA 2012 Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Endocrine Practice 18 988-1028.
31. Garfield D, Hercbergs A & Davis P 2007 Re: hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. Journal of the National Cancer Institute 99 975-976. (doi:10.1093/jnci/djm008)
32. Gereben B, Zavacki AM, Ribich S, Kim BW, Huang SA, Simonides WS, Zeöld A & Bianco AC 2008 Cellular and molecular basis of deiodinaseregulated thyroid hormone signalling. Endocrine Reviews 29 898-938. (doi:10.1210/er.2008-0019)
33. Goodman VL, Rock EP, Dagher R, Ramchandani RP, Abraham S, Gobburu JV, Booth BP, Verbois SL, Morse DE, Liang CY et al. 2007 Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clinical Cancer Research 13 1367-1373. (doi:10.1158/ 1078-0432.CCR-06-2328)
34. Hartmann JT, Haap M, Kopp HG & Lipp HP 2009 Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects. Current Drug Metabolism 10 470-481. (doi:10.2174/138920009788897975)
35. Hercbergs AA, Goyal LK, Suh JH, Lee S, Reddy CA, Cohen BH, Stevens GH, Reddy SK, PeereboomDM, Elson PJ et al. 2003 Propylthiouracil-induced chemical hypothyroidism with high-dose tamoxifen prolongs survival in recurrent high grade glioma: a phase I/II study. Anticancer Research 23 617-626.
36. Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA & Braverman LE 2002 Serum TSH, T(4) , and thyroid antibodies in the United States population (1988 to 1994) : National Health and Nutrition Examination Survey (NHANES III) . Journal of Clinical Endocrinology and Metabolism 87 489-499. (doi:10.1210/ jc.87.2.489)
37. Houk BE, Bello CL, Poland B, Rosen LS, Demetri GD & Motzer RJ 2010 Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of pharmacokinetic/- pharmacodynamic meta-analysis. Cancer Chemotherapy and Pharmacology 66 357-371. (doi:10.1007/s00280-009-1170-y)
38. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I et al. 2007 Temsirolimus, interferon a, or both for advanced renal-cell carcinoma. New England Journal of Medicine 356 2271-2281. (doi:10.1056/ NEJMoa066838)
39. Hurwitz H, Dowlati A, Savage S, Fernando N, Lasalvia S, Whitehead B, Suttle B, Collins D, Ho P & Pandite L 2005 Safety, tolerability and pharmacokinetics of oral administration of GW786034 in pts with solid tumors. Journal of Clinical Oncology 23 195s (suppl; abstr 3012) . (doi:10.1200/JCO. 2005.10.017)
40. Hutson TE, Davis ID, Machiels JH, de Souza PL, Baker K, Bordogna W, Westlund R, Crofts T, Pandite L & Figlin RA 2008a Predictive and prognostic factors in phase II renal cell carcinoma trial with pazopanib (GW786034) , a multi-kinase angiogenesis inhibitor. Annals of Oncology 19 viii187 (suppl 8; abstr 5780) . (doi:10.1093/annonc/mdn510)
41. Hutson TE, Davis ID, Machiels JH, de Souza PL, Baker K, Bordogna W, Westlund R, Crofts T, Pandite L & Figlin RA 2008b Biomarker analysis and final efficacy and safety results of a phase II renal cell carcinoma trial with pazopanib (GW786034) , a multi-kinase angiogenesis inhibitor. Journal of Clinical Oncology 26 261s (abstr 5046)
42. Illouz F, Laboureau-Soares S, Dubois S, Rohmer V & Rodien P 2009 Tyrosine kinase inhibitors and modifications of thyroid function tests: a review. European Journal of Endocrinology 160 331-336. (doi:10.1530/EJE-08- 0648)
43. Kamba T, Tam BY, Hashizume H, Haskell A, Sennino B, Mancuso MR, Norberg SM, O'Brien SM, Davis RB, Gowen LC et al. 2006 VEGFdependent plasticity of fenestrated capillaries in the normal adult microvasculature. American Journal of Physiology. Heart and Circulatory Physiology 290 H560-H576. (doi:10.1152/ajpheart.00133.2005)
44. Kappers MH, van Esch JH, Smedts FM, de Krijger RR, Eechoute K, Mathijssen RH, Sleijfer S, Leijten F, Danser AH, van den Meiracker AH et al. 2011 Sunitinib-induced hypothyroidism is due to induction of type 3 deiodinase activity and thyroidal capillary regression. Journal of Clinical Endocrinology and Metabolism 96 3087-3094. (doi:10.1210/jc. 2011-1172)
45. Kohrle J 2000 The selenoenzyme family of deiodinase isozymes controls local thyroid hormone availability. Reviews in Endocrine & Metabolic Disorders 1 49-58. (doi:10.1023/A:1010012419869)
46. Kollmannsberger C, Bjarnason G, Burnett P, Creel P, Davis M, Dawson N, Feldman D, George S, Hershman J, Lechner T et al. 2011 Sunitinib in metastatic renal cell carcinoma: recommendation for management of noncardiovascular toxicities. Oncologist 16 543-553. (doi:10.1634/ theoncologist.2010-0263)
47. La Plant KD & Louzon PD 2010 Pazopanib: an oral multitargeted tyrosine kinase inhibitor for use in renal cell carcinoma. Annals of Pharmacotherapy 44 1054-1060. (doi:10.1345/aph.1M251)
48. Leese GP, Flynn RV, Jung RT, Macdonald TM, Murphy MJ & Morris AD 2008 Increasing prevalence and incidence of thyroid disease in Tayside. Scotland: the Thyroid Epidemiology Audit and Research Study (TEARS) Clinical Endocrinology 68 311-316.
49. Le Tourneau C, Faivre S & Raymond E 2008 New developments in multitargeted therapy for patients with solid tumours. Cancer Treatment Reviews 34 37-48. (doi:10.1016/j.ctrv.2007.09.003)
50. Ljungberg B, Cowan NC, Hanbury DC, HoraM, KuczykMA, Merseburger AS, Patard JJ, Mulders PF & Sinescu IC 2010 Guidelines on renal cell carcinoma. European Urology.
51. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A et al. 2008 Sorafenib in advanced hepatocellular carcinoma. New England Journal of Medicine 359 378-390. (doi:10.1056/NEJMoa0708857)
52. Lopez-Beltran A, Carrasco JC, Cheng L, Scarpelli M, Kirkali Z & Montironi R 2009 update on the classification of renal epithelial tumors in adults. International Journal of Urology 16 432-443. (doi:10.1111/j.1442-2042. 2009.02302.x)
53. Makita N & Iiri T 2013 Tyrosine kinase inhibitor-induced thyroid disorders: a review and hypothesis. Thyroid 23 151-159. (doi:10.1089/thy.2012. 0456)
54. Makita N, Miyakawa M, Fujita T & Iiri T 2010 Sunitinib induces hypothyroidism with a markedly reduced vascularity. Thyroid 20 323-326. (doi:10.1089/thy.2009.0414)
55. Mannavola D, Coco P, Vannucchi G, Bertuelli R, Carletto M, Casali PG, Beck-Peccoz P & Fugazzola L 2007 A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake. Journal of Clinical Endocrinology and Metabolism 92 3531-3534. (doi:10.1210/jc.2007-0586)
56. Mathew A, Devesa SS, Fraumeni JF Jr & Chow WH 2002 Global increases in kidney cancer incidence, 1973-1992. European Journal of Cancer Prevention 11 171-178. (doi:10.1097/00008469-200204000-00010)
57. Matikainen T, Perez GI, Zheng TS, Kluzak TR, Rueda BR, Flavell RA &Tilly JL 2001 Caspase-3 gene knockout defines cell lineage specificity for programmed cell death signaling in the ovary. Endocrinology 142 2468-2480. (doi:10.1210/en.142.6.2468)
58. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB et al. 2003 In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clinical Cancer Research 9 327-337.
59. Miyake H, Kurahashi T, Yamanaka K, Kondo Y, Muramaki M, Takenaka A, Inoue TA & Fujisawa M 2010 Abnormalities of thyroid function in Japanese patients with metastatic renal cell carcinoma treated with sorafenib: A prospective evaluation. Urologic Oncology 28 515-519. (doi:10.1016/j.urolonc.2009.08.011)
60. Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, DePrimo SE et al. 2006 Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and plateletderived growth factor receptor, in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology 24 16-24. (doi:10.1200/JCO.2005.02.2574)
61. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST et al. 2007 Sunitinib versus interferon a in metastatic renal-cell carcinoma. New England Journal of Medicine 356 115-124. (doi:10.1056/NEJMoa065044)
62. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N et al. 2008 Efficacy of everolimus in advanced renal cell carcinoma: a double blind, randomised, placebo-controlled phase III trial. Lancet 372 449-456. (doi:10.1016/S0140- 6736(08) 61039-9)
63. Motzer RJ, Hutson TE, Tomczak P,MichaelsonMD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA et al. 2009 Overall survival and updated results for sunitinib compared with interferon a in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology 27 3584-3590. (doi:10.1200/JCO.2008.20.1293)
64. Motzer RJ, Hutson TE, Reeves J, Hawkins R, Guo J, Nathan P, Staehler M, De Souza P, Merchan JR, Fife K, et al. 2012 Randomised, open label. Phase III trial of pazopanib versus sunitinib in first-line treatment of patients with metastatic renal cell carcinoma (mRCC) ; results of the COMPARZ trial. Congress of the ESMO, September 28-October 2, 2012, Vienna (abstract 8LBA-PR)
65. Nelson M, Hercbergs A, Rybicki L & Strome M 2006 Association between development of hypothyroidism and improved survival in patients with head and neck cancer. Archives of Otolaryngology, Head & Neck Surgery 132 1041-1046. (doi:10.1001/archotol.132.10.1041)
66. Oberg C, Li J, Pauley A, Wolf E, Gurney M & Lendahl U 2001 The Notch intracellular domain is ubiquitinated and negatively regulated by the mammalian Sel-10 homolog. Journal of Biological Chemistry 276 35847-35853. (doi:10.1074/jbc.M103992200)
67. Oetting A 2007 New insights into thyroid hormone action. Best Practice & Research. Clinical Endocrinology & Metabolism 21 193-208. (doi:10.1016/ j.beem.2007.04.004)
68. O'Farrell AM, Abrams TJ, Yuen HA, Ngai TJ, Louie SG, Yee KW, Wong LM, Hong W, Lee LB, Town A et al. 2003 SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 101 3597-3605. (doi:10.1182/blood-2002-07-2307)
69. Rabinovitch RA, Zelefsky MJ, Gaynor JJ & Fuks Z 1994 Patterns of failure following surgical resection of renal cell carcinoma: implications for adjuvant local and systemic therapy. Journal of Clinical Oncology 12 206-212.
70. Ratain MJ, Eisen T & Stadler WM 2006 Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology 24 2505-2512. (doi:10.1200/JCO. 2005.03.6723)
71. Ries LAG, Melbert D, Krapcho M, et al. 2008 Editors SEER cancer statistics review, 1975-2005. National Cancer Institute.
72. Riesenbeck LM, Bierer S, Hoffmeister I, Köpke T, Papavassilis P, Hertle L, Thielen B & Herrmann E 2011 Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib. World Journal of Urology 29 807-813. (doi:10.1007/s00345- 010-0627-2)
73. Rini BI 2009 Vascular endothelial growth factor-targeted therapy in metastatic renal cell carcinoma. Cancer 115 2306-2312. (doi:10.1002/ cncr.24227)
74. Rini BI, Tamaskar I, Shaheen P, Salas R, Garcia J, Wood L, Reddy S, Dreicer R & Bukowski RM 2007 Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. Journal of the National Cancer Institute 99 81-83. (doi:10.1093/jnci/djk008)
75. Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Ou SS, Archer L, Atkins JN, Picus J, Czaykowski P et al. 2008 Bevacizumab plus interferon a compared with interferon a monotheraphy in patients with metastatic renal cell carcinoma: CALGB 90206. Journal of Clinical Oncology 26 5422-5428. (doi:10.1200/JCO.2008.16.9847)
76. Rini BI, Wilding G, Hudes G, Stadler WM, Kim S, Tarazi J, Rosbrook B, Trask PC, Wood L & Dutcher JP 2009 Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. Journal of Clinical Oncology 27 4462-4468. (doi:10.1200/JCO.2008.21.7034)
77. Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Archer L, Atkins JN, Picus J, Czaykowski P, Dutcher J et al. 2010 Phase III trial of bevacizumab plus interferon a versus interferon a monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. Journal of Clinical Oncology 28 2137-2143. (doi:10.1200/JCO. 2009.26.5561)
78. Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, Michaelson MD, Gorbunova VA, Gore ME, Rusakov IG et al. 2011 Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS) : a randomised phase 3 trial. Lancet 378 1931-1939. (doi:10.1016/S0140- 6736(11) 61613-9)
79. Rivas M & Santisteban P 2003 TSH-activated signaling pathways in thyroid tumorigenesis. Molecular and Cellular Endocrinology 13 31-45. (doi:10.1016/j.mce.2003.10.029)
80. Rixe O, Bukowski RM, Michaelson MD, Wilding G, Hudes GR, Bolte O, Motzer RJ, Bycott P, Liau KF, Freddo J et al. 2007 Axitinib treatment in patients with cytokinerefractory metastatic renal-cell cancer: a phase II study. Lancet Oncology 8 975-984. (doi:10.1016/ S1470-2045(07) 70285-1)
81. Roberts CG & Ladenson PW 2004 Hypothyroidism. Lancet 363 793-803. (doi:10.1016/S0140-6736(04) 15696-1)
82. Rugo HS, Stopeck AT, Joy AA, Chan S, Verma S, Lluch A, Liau KF, Kim S, Bycott P, Rosbrook B et al. 2011 Randomized, placebo-controlled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer. Journal of Clinical Oncology 29 2459-2465. (doi:10.1200/JCO.2010.31.2975)
83. Sabatier R, Eymard JC, Walz J, Deville JL, Narbonne H, Boher JM, Salem N, Marcy M, Brunelle S, Viens P et al. 2012 Could thyroid dysfunction influence outcome in sunitinib-treated metastatic renal cell carcinoma? Annals of Oncology 23 714-721. (doi:10.1093/annonc/mdr275)
84. Salem AK, Fenton MS, Marion KM & Hershman JM 2008 Effect of sunitinib on growth and function of FRTL-5 thyroid cells. Thyroid 18 631-635. (doi:10.1089/thy.2007.0336)
85. Schiller JH, Larson T, Ou SH, Limentani S, Sandler A, Vokes E, Kim S, Liau K, Bycott P, Olszanski AJ et al. 2009 Efficacy and safety of axitinib in patients with advanced nonsmall- cell lung cancer: results from a phase II study. Journal of Clinical Oncology 27 3836-3841. (doi:10.1200/ JCO.2008.20.8355)
86. Schmidinger M, Vogl UM, Bojic M, Lamm W, Heinzl H, Haitel A, Clodi M, Kramer G & Zielinski CC 2011 Hypothyroidism in patients with renal cell carcinoma: blessing or curse? Cancer 117 534-544. (doi:10.1002/ cncr.25422)
87. Schöffski P, Dumez H, Clement P, Hoeben A, Prenen H, Wolter P, Joniau S, Roskams T & Van Poppel H 2006a Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a review. Annals of Oncology 17 1185-1196. (doi:10.1093/annonc/mdj133)
88. Schöffski P, Wolter P, Himpe U, Dychter SS, Baum C, Prenen H, Wildiers H, Bex M & Dumez H 2006b Sunitinib-related thyroid dysfunction: a single center retrospective and prospective evaluation. Journal of Clinical Oncology 24 3092.
89. Schwandt A, Wood LS, Rini B & Dreicer R 2009 Management of side effects associated with sunitinib therapy for patients with renal cell carcinoma. OncoTargets and Therapy 2 51-61.
90. Schwartz CE & Stevenson RE 2007 The MCT8 thyroid hormone transporter and Allan-Herndon-Dudley syndrome. Best Practice & Research. Clinical Endocrinology & Metabolism 21 307-321. (doi:10.1016/j.beem. 2007.03.009)
91. Sella A, Hercbergs AH, Hanovich E & Kovel S 2012 Does sunitinib-induced hypothyroidism play a role in the activity of sunitinib in metastatic renal cell carcinoma? Chemotherapy 58 200-205. (doi:10.1159/ 000337079)
92. Shinohara N, Takahashi M, Kamishima T, Ikushima H, Otsuka N, Ishizu A, Shimizu C, Kanayama H & Nonomural K 2011 The incidence and mechanism of sunitinib-induced thyroid atrophy in patients with metastatic renal cell carcinoma. British Journal of Cancer 104 241-247. (doi:10.1038/sj.bjc.6606029)
93. Simonides WS, Mulcahey MA, Redout EM, Muller A, Zuidwijk MJ, Visser TJ, Wassen FW, Crescenzi A, da-Silva WS, Harney J et al. 2008 Hypoxiainducible factor induces local thyroid hormone inactivation during hypoxic-ischemic disease in rats. Journal of Clinical Investigation 118 975-983.
94. Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA, Kavina A et al. 2010 Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. Journal of Clinical Oncology 28 1061-1068. (doi:10.1200/ JCO.2009.23.9764)
95. Sukocheva OA & Carpenter DO 2006 Anti-apoptotic effects of 3,5,30- triiodothyronine in mouse hepatocytes. Journal of Endocrinology 191 447-458. (doi:10.1677/joe.1.07061)
96. Sulkes A 2010 Novel multitargeted anticancer oral therapies: sunitinib and sorafenib as a paradigm. Israel Medical Association Journal 12 628-632.
97. Tamaskar I, Bukowski R, Elson P, Ioachimescu AG, Wood L, Dreicer R, Mekhail T, Garcia J & Rini BI 2008 Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib. Annals of Oncology 19 265-268. (doi:10.1093/annonc/mdm483)
98. Tomita Y, Uemura H, Fujimoto H, Kanayama HO, Shinohara N, Nakazawa H, Imai K, Umeyama Y, Ozono S, Naito S et al. 2011 Key predictive factors of axitinib (AG-013736) -induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma. European Journal of Cancer 47 2592-2602. (doi:10.1016/j.ejca.2011.07.014)
99. Torino F, Corsello SM, Longo R, Barnabei A & Gasparini G 2009 Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy. Nature Reviews. Clinical Oncology 6 219-228. (doi:10.1038/nrclinonc.2009.4)
100. Trentin AG, Alvarez-Silva M & Moura Neto V 2001 Thyroid hormone induces cerebellar astrocytes and C6 glioma cells to secrete mitogenic growth factors. American Journal of Physiology. Endocrinology and Metabolism 281 E1088-E1094.
101. TunbridgeWM, Evered DC, Hall R, Appleton D, BrewisM, Clark F, Evans JG, Young E, Bird T & Smith PA 1977 The spectrum of thyroid disease in a community: the Whickham survey. Clinical Endocrinology 7 481-493. (doi:10.1111/j.1365-2265.1977.tb01340.x)
102. Utiger RD 1965 Radioimmunoassay of human plasma thyrotropin. Journal of Clinical Investigation 44 1277-1286. (doi:10.1172/JCI105234)
103. Vakkalanka BK, Elson P, Wood L, Dreicer R, Garcia JA, Bukowski RM & Rini BI 2008 Long term toxicity of tyrosine kinase inhibitors (TKIs) in patients with metastatic clear cell renal cell carcinoma (RCC) 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) ; Chicago, Illinois, May 30-June 3, 2008.
104. Vanderpump MP, Tunbridge WM, French JM, Appleton D, Bates D, Clark F, Grimley Evans J, Hasan DM, Rodgers H & Tunbridge F 1995 The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham survey. Clinical Endocrinology 43 55-68. (doi:10.1111/j.1365-2265.1995.tb01894. x)
105. Verga Falzacappa C, Panacchia L, Bucci B, Stigliano A, Gisella Cavallo M, Brunetti E, Toscano V & Misitil S 2006 3,5,30-Triiodothyronine (T3) is a survival factor for pancreatic b-cells undergoing apoptosis. Journal of Cellular Physiology 206 309-321. (doi:10.1002/jcp.20460)
106. Verga Falzacappa C, Mangialardo C, Patriarca V, Bucci B, Amendola D, Raffa S, Torrisi MR, Silvestrini G, Ballanti P, Moriggi G et al. 2009 Thyroid hormones induce cell proliferation and survival in ovarian granulosa cells COV 434. Journal of Cellular Physiology 221 242-253. (doi:10.1002/jcp.21849)
107. Verga Falzacappa C, Timperi E, Bucci B, Amendola D, Piergrossi P, D'Amico D, Santaguida MG, Centanni M & Misiti S 2012 T3 preserves ovarian granulosa cells from chemotherapy-induced apoptosis. Journal of Endocrinology 215 281-289. (doi:10.1530/JOE-12-0153)
108. VetterML, Kaul S& Iqbal N 2008 Tyrosine kinase inhibitors and the thyroid as both an unintended and an intended target. Endocrine Practice 14 618-624. (doi:10.4158/EP.14.5.618)
109. Wang JF, Milosveski V, Schramek C, Fong GH, Becks GP & Hill DJ 1998 Presence and possible role of vascular endothelial growth factor in thyroid cell growth and function. Journal of Endocrinology 157 5-12. (doi:10.1677/joe.0. 1570005)
110. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M et al. 2004 BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Research 64 7099-7109. (doi:10.1158/0008- 5472.CAN-04-1443)
111. Wolter P, Dumez H & Schöffski P 2007 Sunitinib and hypothyroidism. New England Journal of Medicine 356 1580-1581. (doi:10.1056/ NEJMc070327)
112. Wolter P, StefanC,Decallonne B,DumezH, Bex M, Carmeliet P&Schöffski P 2008 The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation. British Journal of Cancer 99 448-454. (doi:10.1038/sj.bjc.6604497)
113. Wong E, Rosen LS, Mulay M, Vanvugt A, Dinolfo M, Tomoda C, SugawaraM & Hershman JM 2007 Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity. Thyroid 17 351-355. (doi:10.1089/thy.2006.0308)
114. Zhang C, Xia G & Tsang BK 2011 Interactions of thyroid hormone and FSH in the regulation of rat granulosa cell apoptosis. Frontiers in Bioscience 1 1401-1413.
115. Zygulska AL, Krzemieniecki K & Sowa-Staszczak A 2012 Hypothyroidism during treatment with tyrosine kinase inhibitors. Endokrynologia Polska 63 302-306.